real-time news and commentary for investors
Friday, Oct 18
Ariad ends testing of leukemia drug; shares crumble
- Ariad (ARIA) has ended the Phase III trial of its Iclusig treatment for chronic myeloid leukemia after patients suffered severe cardiac problems, with the FDA investigating reports of blood clots, fatal heart attacks, worsening coronary artery disease, stroke and the narrowing of large arteries of the brain.
- Ariad had put the trial on partial hold last week.
- Iclusig is approved in the EU and U.S. for certain types of leukemia, but Ariad will make labeling changes to the drug to reflect the cardiac issues.
- Shares collapse 36%. (PR)